In endocrine-resistant, ER+ breast cancer models, alisertib, a selective inhibitor of AURKA, was found to reverse stemness reprogramming and thereby restore the CD44−/CD24+ phenotype, ERα expression, and sensitivity to endocrine therapy [14, 15]. Here, CD44 is linked to breast carcinoma.